韩美药品的‘Gugutams’将在墨西哥以‘Aditams’上市，标志着全面进军拉丁美洲的开始-动脉网

Hanmi Pharmaceutical's 'Gugutams' to be Launched in Mexico as 'Aditams', Marking the Start of Full-Scale Latin America Expansion

CISION 等信源发布 2025-04-02 12:17



可切换为仅中文







Hanmi Pharm Begins Local Sales of Urological Product 'Aditams' in

韩美药品开始在本地销售泌尿科产品“Aditams”

Mexico

墨西哥

with Partner 'Laboratorios Silanes'

与合作伙伴“Laboratorios Silanes”

Launch completed in February, Hanmi Pharm's Third Product to

发射于二月完成，韩美制药的第三款产品

Enter

输入

Latin America

拉丁美洲

Aditams, The First Urological Combination Drug for OPG and ED Exported to

阿迪塔姆斯，首个用于OPG和ED的泌尿科复方药物出口到

Mexico

墨西哥

SEOUL, South Korea

韩国首尔

，

April 2, 2025

2025年4月2日

/PRNewswire/ -- Hanmi Pharmaceutical's combination therapy for Obstructive Prostatic Growth (OPG) caused by Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED), Gugutams, is entering the Mexican market under the local brand name 'Aditams.'

/PRNewswire/ -- 韩美制药的组合疗法Gugutams，用于治疗因良性前列腺增生（BPH）和勃起功能障碍（ED）引起的梗阻性前列腺增生（OPG），正以当地品牌名“Aditams”进入墨西哥市场。

继续阅读

Aditams

阿迪塔姆斯

Hanmi Pharmaceutical announced that it has completed the launch of Aditams in

韩美药品宣布，已完成Aditams的上市工作。

Mexico

墨西哥

under the export agreement signed in

根据签署的出口协议

October 2020

2020年10月

with the Mexican pharmaceutical company 'Laboratorios Silanes'. Under the agreement, Hanmi Pharmaceutical plans to export Gugutams to the Mexican market for a period of

与墨西哥制药公司“Laboratorios Silanes”合作。根据协议，韩美制药计划将Gugutams出口到墨西哥市场，为期

seven

七

years, starting

年，开始

在

February 2025

2025年2月

。

Gugutams, developed by Hanmi Pharmaceutical, is the world's first urological

由韩美制药开发的Gugutams是世界上第一个泌尿科相关的药物。

combination therapy

联合疗法

combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). It is also noteworthy as the first prescription drug in Korea to apply Poly-Cap technology, which integrates multiple active ingredients into a single capsule..

结合两种活性成分：治疗阻塞性前列腺增生（OPG）的坦索罗辛和治疗勃起功能障碍（ED）的他达拉非。值得注意的是，它还是韩国首个应用Poly-Cap技术的处方药，该技术将多种活性成分整合到一粒胶囊中。

Laboratorios Silanes, a leading pharmaceutical company in

西拉内斯实验室，一家领先的制药公司ใน

Mexico

墨西哥

founded in 1943, is committed to providing innovative healthcare solutions and driving rapid growth in the industry. It has established itself as a key player in the Latin American pharmaceutical market through its robust distribution network and strategic collaborations with global partners.

成立于1943年，致力于提供创新的医疗保健解决方案并推动行业的快速增长。它通过强大的分销网络和与全球合作伙伴的战略合作，已在拉丁美洲制药市场确立了重要地位。

Silanes previously collaborated with Hanmi Pharmaceutical in 2023 to successfully introduce the hypertension and dyslipidemia combination treatment 'Amosartan Q', under the local brand 'Lodarta' and in 2024 to introduce the combination hypertension treatment 'Amosartan Plus' under the local brand 'Bicartial-CTD'.

2023年，Silanes曾与韩美制药合作，成功推出了高血压和血脂异常的复方治疗药物“阿莫沙坦Q”（本地品牌名为Lodarta），并在2024年推出了复方高血压治疗药物“阿莫沙坦Plus”（本地品牌名为Bicartial-CTD）。

。

Following these products, Gugutams, under the local brand 'Aditams', becomes Hanmi Pharmaceutical's third product in the Latin American region.

继这些产品之后，Gugutams以当地品牌“Aditams”成为韩美制药在拉丁美洲地区的第三款产品。

Aditams, as the first urological combination therapy to enter the Mexican market, is expected to offer a new treatment option for patients suffering from both Obstructive Prostatic Growth (OPG) and erectile dysfunction (ED). By managing both conditions with a single medication, it significantly enhances patient convenience and maximizes therapeutic efficacy..

Aditams作为首个进入墨西哥市场的泌尿科复方疗法，预计将为同时患有阻塞性前列腺增生（OPG）和勃起功能障碍（ED）的患者提供一种新的治疗选择。通过单一药物同时管理这两种病症，极大地提高了患者的便利性并最大化治疗效果。

Hanmi continues to focus on expanding its partnerships in emerging markets such as the

韩美继续专注于扩大其在新兴市场的合作伙伴关系，如

Middle East

中东地区

and

和

Latin America

拉丁美洲

, in addition to its established presence in developed markets like

，除了在发达国家市场等已有稳固地位的市场之外

North America

北美

and

和

Japan

日本

. The company aims to leverage strategic partners like Laboratorios Silanes as key footholds to broaden its product portfolio and regional reach.

该公司旨在利用像Laboratorios Silanes这样的战略合作伙伴作为关键支撑，以扩大其产品组合和区域覆盖范围。

Park Jae

朴宰

-hyun

-贤

，

CEO of Hanmi Pharmaceutical, stated, 'As the first urological combination therapy to enter the Mexican market, Gugutams is expected to present a new treatment paradigm for local patients.' He added, 'Through this collaboration with Laboratorios Silanes, we aim to solidify Hanmi Pharmaceutical's presence in the Latin American market and leverage this as a foundation to further strengthen our competitiveness in the global pharmaceutical industry.'.

韩美制药社长表示：“作为首个进入墨西哥市场的泌尿科复方药物，Gugutams有望为当地患者提供一种新的治疗模式。”他补充道：“通过与Silanes实验室的合作，我们旨在巩固韩美制药在拉丁美洲市场的地位，并以此为基础进一步提升我们在全球制药行业的竞争力。”

Official Websites:

官方网站：

www.hanmipharm.com

About Hanmi Pharmaceutical:

关于韩美制药：

Hanmi Pharmaceutical is an R&D-focused pharmaceutical company

韩美制药是一家专注于研发的制药公司。

committed to

致力于

developing globally

全球发展

innovative

创新的

therapies in areas of high unmet medical needs such as obesity/metabolism, oncology, and rare

在肥胖/代谢、肿瘤学和罕见病等高未满足医疗需求领域的疗法

diseases

疾病

. Hanmi leverages proprietary platform technologies, including long-acting biologics and bispecific antibodies, to address unmet medical needs. The company emphasizes

韩美利用包括长效生物制品和双特异性抗体在内的专有平台技术，来满足未被满足的医疗需求。该公司强调

open

打开

innovation and has established numerous global

创新并建立了众多全球性的

partnerships

伙伴关系

to advance its research and development efforts.

推进其研发工作。

SOURCE Hanmi Pharmaceutical

来源：韩美制药

WANT YOUR COMPANY'S NEWS